Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Investigating the Role of the MNK1/2-eIF4E Signaling Axis by Spatially Profiling the Human Breast Cancer Tissue Tumor Microenvironment using Phenocylcer (CODEX) Multiplex Imaging
FY 2023-24
Summary
Our lab has previously shown that the chemical modification of the protein eIF4E causes elevated production of metastasis-supporting proteins in tumor cells. Modified eIF4E affects a network of cells surrounding the tumor, called the tumor microenvironment (TME), which includes immune cells, extracellular matrix (ECM), blood vessels, and fibroblasts. We have shown that modified eIF4E, specifically in cancer-associated fibroblasts (CAFs), an activated form of fibroblast, supports breast cancer metastasis. We are now seeking to understand the underlying reason. CAFs are the architects of the TME; they receive signals from the tumor to remodel the environment around them. To do so, CAFs transform into subtypes with distinct functions. Two main CAF subtypes have been identified: myCAFs and iCAFs. MyCAFS are primarily responsible for modifying the structure of ECM in the TME, and iCAFs contribute to immune cell suppression. We hypothesize that modified eIF4E participates in CAF subtype differentiation, helping the different CAF subsets to develop their functional capacity, possibly in response to distinct spatial cues in the TME. We will test this by imaging mouse and human tumor samples using state-of-the-art imaging to understand the localization of CAF subtypes and their interaction with other cells within the TME. Our findings may highlight the use of pre-existing drugs that limit the amount of chemically altered eIF4E as a new therapeutic option for patients undergoing breast cancer treatment.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
497065
Name
McCallum Paige
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the Role of the MNK1/2-eIF4E Signaling Axis by Spatially Profiling the Human Breast Cancer Tissue Tumor Microenvironment using Phenocylcer (CODEX) Multiplex Imaging
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cancer Associated Fibroblasts; Cancer Therapy; Cell Signaling; Machine Learning; Metastasis; Mrna Regulation; Multiplexed Imaging; Protein Expression; Spatial Biology; Tumor Microenvironment
Abstract
Our lab has previously shown that the chemical modification of the protein eIF4E causes elevated production of metastasis-supporting proteins in tumor cells. Modified eIF4E affects a network of cells surrounding the tumor, called the tumor microenvironment (TME), which includes immune cells, extracellular matrix (ECM), blood vessels, and fibroblasts. We have shown that modified eIF4E, specifically in cancer-associated fibroblasts (CAFs), an activated form of fibroblast, supports breast cancer metastasis. We are now seeking to understand the underlying reason. CAFs are the architects of the TME; they receive signals from the tumor to remodel the environment around them. To do so, CAFs transform into subtypes with distinct functions. Two main CAF subtypes have been identified: myCAFs and iCAFs. MyCAFS are primarily responsible for modifying the structure of ECM in the TME, and iCAFs contribute to immune cell suppression. We hypothesize that modified eIF4E participates in CAF subtype differentiation, helping the different CAF subsets to develop their functional capacity, possibly in response to distinct spatial cues in the TME. We will test this by imaging mouse and human tumor samples using state-of-the-art imaging to understand the localization of CAF subtypes and their interaction with other cells within the TME. Our findings may highlight the use of pre-existing drugs that limit the amount of chemically altered eIF4E as a new therapeutic option for patients undergoing breast cancer treatment.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
McCallum, Paige
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~